EGE
MCID: ESN005
MIFTS: 52

Eosinophilic Gastroenteritis (EGE)

Categories: Gastrointestinal diseases, Rare diseases

Aliases & Classifications for Eosinophilic Gastroenteritis

MalaCards integrated aliases for Eosinophilic Gastroenteritis:

Name: Eosinophilic Gastroenteritis 12 76 59 55 15 73
Eosinophilic Gastroenterocolitis 59
Gastroenteritis, Eosinophilic 76
Eosinophilic Enteropathy 73
Eosinophilic Enteritis 59
Ege 59

Characteristics:

Orphanet epidemiological data:

59
eosinophilic gastroenteritis
Inheritance: Not applicable; Age of onset: All ages; Age of death: normal life expectancy;

Classifications:



Summaries for Eosinophilic Gastroenteritis

MalaCards based summary : Eosinophilic Gastroenteritis, also known as eosinophilic gastroenterocolitis, is related to gastroenteritis and esophagitis. An important gene associated with Eosinophilic Gastroenteritis is CCL11 (C-C Motif Chemokine Ligand 11), and among its related pathways/superpathways are JAK-STAT signaling pathway (KEGG) and Allograft rejection. The drugs Fluticasone and Budesonide have been mentioned in the context of this disorder. Affiliated tissues include colon, small intestine and testes, and related phenotypes are dysphagia and vomiting

Wikipedia : 76 Eosinophilic gastroenteritis (EG) is a rare and heterogeneous condition characterized by patchy or... more...

Related Diseases for Eosinophilic Gastroenteritis

Diseases related to Eosinophilic Gastroenteritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 183)
# Related Disease Score Top Affiliating Genes
1 gastroenteritis 30.9 ALB CCL11 IL5 RNASE3 TSLP
2 esophagitis 30.3 CCL11 IL5 TSLP
3 esophagitis, eosinophilic, 1 30.3 CCL11 IL5 TSLP
4 hypereosinophilic syndrome, idiopathic 30.2 IL3 IL5
5 milk allergy 30.1 IL5 RNASE3
6 churg-strauss syndrome 30.0 IL5 RNASE3
7 dermatitis 29.9 CCL11 IL5 TSLP
8 allergic bronchopulmonary aspergillosis 29.9 EPX IL5
9 eosinophilic granuloma 29.8 EPX RNASE3
10 food allergy 29.7 ALB EPX IL5 RNASE3
11 hypereosinophilic syndrome 29.7 CCL11 EPX IL3 IL5 RNASE3
12 chronic eosinophilic pneumonia 29.5 CCL11 IL5 RNASE3
13 eosinophilic pneumonia 29.5 CCL11 IL3 IL5 RNASE3
14 asthma 29.4 CCL11 EPX IL3 IL5 RNASE3 TSLP
15 bronchitis 29.2 ALB CCL11 IL5 RNASE3
16 inflammatory bowel disease 29.2 ALB CCL11 EPX IL5
17 allergic asthma 29.1 CCL11 EPX IL5 RNASE3 TSLP
18 allergic hypersensitivity disease 28.9 CCL11 EPX IL3 IL5 RNASE3 TSLP
19 eosinophilic enteropathy 11.9
20 megalencephaly-capillary malformation-polymicrogyria syndrome 11.0
21 aplastic anemia 11.0
22 exercise-induced anaphylaxis 11.0
23 paroxysmal cold hemoglobinuria 11.0
24 protein-losing enteropathy 10.3
25 pancreatitis 10.3
26 colitis 10.2
27 pyloric stenosis 10.2
28 duodenal ulcer 10.2
29 acute pancreatitis 10.2
30 seborrheic infantile dermatitis 10.2 IL3 IL5
31 duodenal obstruction 10.1
32 pemphigoid gestationis 10.1 CCL11 IL5
33 chronic meningitis 10.1 CCL11 IL5
34 angiostrongyliasis 10.1 CCL11 IL5
35 strongyloidiasis 10.1 CCL11 IL5
36 loeffler endocarditis 10.1 IL5 RNASE3
37 eosinophilic meningitis 10.1 CCL11 IL5
38 paragonimiasis 10.1 IL5 RNASE3
39 cough variant asthma 10.1 IL5 RNASE3
40 cow milk allergy 10.1 IL5 RNASE3
41 folliculitis 10.1 CCL11 IL5
42 radiculopathy 10.1 CCL11 IL5
43 latex allergy 10.1 IL5 RNASE3
44 status asthmaticus 10.1 IL5 RNASE3
45 blepharoconjunctivitis 10.1 CCL11 RNASE3
46 crohn's disease 10.1
47 obstructive jaundice 10.1
48 cystitis 10.1
49 intestinal obstruction 10.1
50 eosinophilic cystitis 10.1

Graphical network of the top 20 diseases related to Eosinophilic Gastroenteritis:



Diseases related to Eosinophilic Gastroenteritis

Symptoms & Phenotypes for Eosinophilic Gastroenteritis

Human phenotypes related to Eosinophilic Gastroenteritis:

59 32 (show all 22)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 dysphagia 59 32 frequent (33%) Frequent (79-30%) HP:0002015
2 vomiting 59 32 frequent (33%) Frequent (79-30%) HP:0002013
3 ascites 59 32 occasional (7.5%) Occasional (29-5%) HP:0001541
4 anemia 59 32 frequent (33%) Frequent (79-30%) HP:0001903
5 abdominal pain 59 32 frequent (33%) Frequent (79-30%) HP:0002027
6 edema 59 32 occasional (7.5%) Occasional (29-5%) HP:0000969
7 weight loss 59 32 occasional (7.5%) Occasional (29-5%) HP:0001824
8 asthma 59 32 occasional (7.5%) Occasional (29-5%) HP:0002099
9 hematochezia 59 32 occasional (7.5%) Occasional (29-5%) HP:0002573
10 elevated c-reactive protein level 59 32 frequent (33%) Frequent (79-30%) HP:0011227
11 eosinophilia 59 32 hallmark (90%) Very frequent (99-80%) HP:0001880
12 elevated erythrocyte sedimentation rate 59 32 occasional (7.5%) Occasional (29-5%) HP:0003565
13 hypoalbuminemia 59 32 frequent (33%) Frequent (79-30%) HP:0003073
14 steatorrhea 59 32 frequent (33%) Frequent (79-30%) HP:0002570
15 allergic rhinitis 59 32 frequent (33%) Frequent (79-30%) HP:0003193
16 atopic dermatitis 59 32 occasional (7.5%) Occasional (29-5%) HP:0001047
17 protein-losing enteropathy 59 32 occasional (7.5%) Occasional (29-5%) HP:0002243
18 malabsorption 59 Frequent (79-30%)
19 leukocytosis 59 Frequent (79-30%)
20 diarrhea 59 Frequent (79-30%)
21 abnormality of the gastrointestinal tract 59 Frequent (79-30%)
22 abnormal test result 59 Frequent (79-30%)

Drugs & Therapeutics for Eosinophilic Gastroenteritis

Drugs for Eosinophilic Gastroenteritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 125)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluticasone Approved, Experimental Phase 4,Phase 3,Phase 2,Not Applicable 90566-53-3 62924
2
Budesonide Approved Phase 4,Phase 3,Phase 2,Not Applicable 51333-22-3 63006 5281004
3
Alginic acid Approved, Investigational Phase 4 9005-32-7
4
Dexlansoprazole Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 103577-45-3, 138530-94-6 9578005
5
Lansoprazole Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 103577-45-3 3883
6 Anti-Asthmatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7 Respiratory System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8 Dermatologic Agents Phase 4,Phase 3,Phase 2,Not Applicable
9 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
10 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Not Applicable
11 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
12 Anti-Allergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Bronchodilator Agents Phase 4,Phase 3,Phase 2,Not Applicable
14 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Autonomic Agents Phase 4,Phase 3,Phase 2,Not Applicable
16 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 Cromolyn Sodium Phase 4
18 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Not Applicable
19 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Soy Bean Phase 4,Phase 2,Phase 3,Not Applicable
21 Olive Phase 4
22 Antacids Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
23 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
24 Anti-Ulcer Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
25 Proton Pump Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
26
Montelukast Approved Phase 3,Phase 1,Not Applicable 158966-92-8 5281040
27 Reslizumab Approved, Investigational Phase 3,Phase 2
28
Esomeprazole Approved, Investigational Phase 2, Phase 3,Not Applicable 161796-78-7, 119141-88-7 4594 9579578
29
Ketotifen Approved Phase 3 34580-14-8, 34580-13-7 3827
30
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
31 Leukotriene Antagonists Phase 3,Phase 1,Not Applicable
32 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable
33 Immunoglobulins Phase 3,Phase 2,Phase 1
34 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
35 Antibodies Phase 3,Phase 2,Phase 1
36 Antipruritics Phase 3,Not Applicable
37 Neurotransmitter Agents Phase 3,Phase 2,Not Applicable
38
Histamine Phosphate Phase 3 51-74-1 65513
39 Histamine H1 Antagonists Phase 3
40 Histamine Antagonists Phase 3
41
Omalizumab Approved, Investigational Phase 2,Phase 1 242138-07-4
42
Infliximab Approved Phase 2 170277-31-3
43 tannic acid Approved Phase 2,Not Applicable
44
Benzocaine Approved, Investigational Phase 2,Not Applicable 94-09-7, 1994-09-7 2337
45
Angiotensin II Approved, Investigational Phase 2 11128-99-7, 68521-88-0, 4474-91-3 172198 65143
46
Losartan Approved Phase 2 114798-26-4 3961
47
Bethanechol Approved Phase 2 674-38-4 2370
48
mometasone furoate Approved, Vet_approved Phase 2 83919-23-7
49 Indoleacetic Acids Phase 2
50 Antirheumatic Agents Phase 2

Interventional clinical trials:

(show top 50) (show all 137)
# Name Status NCT ID Phase Drugs
1 Oral Cromolyn Sodium for the Treatment of Eosinophilic Esophagitis Completed NCT02371941 Phase 4 oral cromolyn sodium;Placebo
2 Dietetic Versus Topical Steroids for Pediatric Eosinophilic Esophagitis Completed NCT01846962 Phase 4 Budesonide;Fluticasone;Oral Viscous Budesonide (OVB)
3 EoE RCT Fluticasone and Omeprazole vs Fluticasone Alone Recruiting NCT03781596 Phase 4 Fluticasone;Omeprazole;Placebo oral capsule
4 Budesonide Versus Fluticasone for Treatment of Eosinophilic Esophagitis Active, not recruiting NCT02019758 Phase 4 Oral Viscous Budesonide;Fluticasone MDI;Placebo slurry;Placebo inhaler
5 The Frequency of Eosinophilic Esophagitis in Patients With Heartburn That is Refractory to Proton Pump Inhibitors Terminated NCT01404832 Phase 4 Treat with lansoprazole 30 mg BID for 2 weeks, endoscopic examination with esophageal biopsy for patients with persistent symptoms
6 Eosinophilic Esophagitis Treatment: Montelukast vs Fluticasone Unknown status NCT01702701 Phase 3 Montelukast;Fluticasone
7 Open-Label Extension Study of Reslizumab in Pediatric Subjects With Eosinophilic Esophagitis Completed NCT00635089 Phase 3 reslizumab
8 Budesonide Orodispersible Tablet vs. Placebo in Active Eosinophilic Esophagitis Completed NCT02434029 Phase 3 Budesonide 1mg orodispersible tablet twice daily;Placebo orodispersible tablet twice daily
9 Efficacy and Safety Study of Reslizumab to Treat Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years Completed NCT00538434 Phase 2, Phase 3
10 Eosinophilic Esophagitis Intervention Trial-1 Food vs. 4 Food Elimination Diet Followed by Swallowed Glucocorticoids Completed NCT02610816 Phase 2, Phase 3 Fluticasone Propionate, 800 mcg twice daily (post 4FED failure)
11 A Study Comparing Swallowed Flovent and Placebo in Patients With Eosinophilic Disorders Completed NCT00266578 Phase 3 Fluticasone Propionate
12 The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis Completed NCT00728481 Phase 2, Phase 3 Esomeprazole;Budesonide
13 Maintenance of Remission With Budesonide Orodispersible Tablets vs. Placebo in Eosinophilic Esophagitis Recruiting NCT02493335 Phase 3 Budesonide 0.5mg orodispersible tablet twice daily;Budesonide 1mg orodispersible tablet twice daily;Placebo orodispersible tablet twice daily
14 Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Subjects With Eosinophilic Esophagitis (EoE) Recruiting NCT03245840 Phase 3 Budesonide oral suspension
15 An Extension Study to Evaluate Maintenance of Efficacy and Long-term Treatment Effect of Oral Budesonide Suspension (OBS) in Adults and Adolescents With Eosinophilic Esophagitis (EoE) Recruiting NCT02736409 Phase 3 Oral Budesonide Suspension (OBS);Placebo
16 Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE) Recruiting NCT03633617 Phase 3 Dupilumab;Placebo
17 SOFEED: Six Food vs. One Food Eosinophilic Esophagitis Diet Study Recruiting NCT02778867 Phase 2, Phase 3 Flovent
18 Ketotifen for Children With Functional Dyspepsia in Association With Duodenal Eosinophilia Recruiting NCT02484248 Phase 3 Ketotifen;Placebo
19 A Study in Adolescents and Adults With Eosinophilic Esophagitis (EoE) Measuring Histologic Response and Determine if Reduction in Dysphagia is Achieved Active, not recruiting NCT02605837 Phase 3 Oral Budesonide Suspension (OBS);Placebo
20 Dose-Ranging Study of Oral Viscous Budesonide in Pediatrics With Eosinophilic Esophagitis Completed NCT00762073 Phase 2 budesonide;placebo
21 A Study of Flovent in Patients With Eosinophilic Esophagitis Completed NCT00426283 Phase 2 Flovent
22 Budesonide for Eosinophilic Esophagitis Completed NCT00271349 Phase 2 Budesonide
23 Topical Steroid Treatment for Eosinophilic Esophagitis Completed NCT00275561 Phase 2 Fluticasone;Placebo
24 Budesonide Effervescent Tablets vs. Viscous Budesonide Suspension vs. Placebo in Eosinophilic Esophagitis Completed NCT02280616 Phase 2 low dose budesonide tablet;high dose budesonide tablet;high dose budesonide suspension;Placebo
25 Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis Completed NCT02098473 Phase 2 RPC4046;Placebo
26 Omalizumab to Treat Eosinophilic Gastroenteritis Completed NCT00084097 Phase 2 Omalizumab
27 Proof of Concept Study of OC000459 in Eosinophilic Esophagitis Completed NCT01056783 Phase 2 OC000459;Placebo
28 Use of Topical Budesonide in the Treatment of Eosinophilic Esophagitis Completed NCT00638456 Phase 2 Budesonide plus Prevacid;placebo plus Prevacid
29 Safety and Tolerability Study of Oral EUR-1100 to Treat Eosinophilic Esophagitis Completed NCT01386112 Phase 1, Phase 2 EUR-1100;placebo
30 Efficacy and Safety of QAX576 in Patients With Eosinophilic Esophagitis Completed NCT01022970 Phase 2 QAX576 placebo;QAX576
31 Study of Dupilumab in Adult Patients With Active Eosinophilic Esophagitis (EoE) Completed NCT02379052 Phase 2 Dupilumab;Placebo
32 A Pilot Study of the Treatment of Eosinophilic Esophagitis With Omalizumab Completed NCT00123630 Phase 2 omalizumab;Placebo
33 Comparison of Esomeprazole to Aerosolized, Swallowed Fluticasone for Eosinophilic Esophagitis Completed NCT00123656 Phase 2 esomeprazole;fluticasone
34 OBS in Adolescent and Adults With EOE: A Phase II, Randomized, Double-Blind, Placebo Controlled, Study With an Open Label Extension Completed NCT01642212 Phase 2 Oral Budesonide Suspension (MB-9);Placebo
35 Off Label Use of Infliximab in Adult Patients With Severe Eosinophilic Esophagitis Completed NCT00523354 Phase 2 Infliximab
36 Intravenous Mepolizumab In Children With Eosinophilic Esophagitis Completed NCT00358449 Phase 2 mepolizumab
37 An Evaluation Of Mepolizumab In Therapy Of Eosinophilic Oesophagitis In Adult Patients Completed NCT00274703 Phase 2 mepolizumab
38 Anti-Interleukin-5 Antibody to Treat Hypereosinophilic Syndrome Completed NCT00017862 Phase 2 SCH55700
39 Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome Completed NCT00266565 Phase 1, Phase 2 Mepolizumab
40 A Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis Recruiting NCT03496571 Phase 2 AK002
41 Benralizumab for Eosinophilic Gastritis Recruiting NCT03473977 Phase 1, Phase 2
42 An Open-Label Trial of Losartan Potassium in Participants With Eosinophilic Esophagitis (EoE) Recruiting NCT03029091 Phase 2 Losartan Potassium
43 Milk Patch for Eosinophilic Esophagitis Active, not recruiting NCT02579876 Phase 2 Viaskin Milk 500 mcg;Viaskin Placebo
44 Eosinophilic Esophagitis Clinical Therapy Comparison Trial Active, not recruiting NCT01821898 Phase 2 Oral Budesonide
45 Efficacy, Safety, and Pharmacokinetics of APT-1011 in Subjects With Eosinophilic Esophagitis (EoE) Active, not recruiting NCT03191864 Phase 2 APT-1011;Placebo
46 Testing Effectiveness of Losartan in Patients With EoE With or Without a CTD Active, not recruiting NCT01808196 Phase 2 Losartan Potassium
47 An Extension Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis Enrolling by invitation NCT03664960 Phase 2 AK002
48 DEGS - Dupilumab for Eosinophilic Gastritis Study Not yet recruiting NCT03678545 Phase 2 Dupilumab (blinded);Placebo (blinded);Dupilumab (open-label)
49 Efficacy and Safety of Three Doses of Florence Oral Suspension in Adults With Eosinophilic Esophagitis Not yet recruiting NCT02873468 Phase 2 Florence 30 μg/mL;Florence 60 μg/mL;Florence 90 μg/mL
50 Mepo for EoE Study Not yet recruiting NCT03656380 Phase 2 Mepolizumab 300 mg;Mepolizumab 100 mg

Search NIH Clinical Center for Eosinophilic Gastroenteritis

Genetic Tests for Eosinophilic Gastroenteritis

Anatomical Context for Eosinophilic Gastroenteritis

MalaCards organs/tissues related to Eosinophilic Gastroenteritis:

41
Colon, Small Intestine, Testes, Liver, Pituitary, Pancreas, Skin

Publications for Eosinophilic Gastroenteritis

Articles related to Eosinophilic Gastroenteritis:

(show top 50) (show all 431)
# Title Authors Year
1
A Case of Eosinophilic Gastroenteritis in Which Obstructive Jaundice Developed due to Invagination of the Duodenal Wall. ( 29434146 )
2018
2
Vedolizumab Treatment May Reduce Steroid Burden and Improve Histology in Patients With Eosinophilic Gastroenteritis. ( 29596982 )
2018
3
Eosinophilic gastroenteritis presenting with gastric perforation. ( 29366927 )
2018
4
Successful Food-Elimination Diet in an Adult with Eosinophilic Gastroenteritis. ( 29850645 )
2018
5
Ascites in a Young Woman: A Rare Presentation of Eosinophilic Gastroenteritis. ( 29862093 )
2018
6
Eosinophilic Gastroenteritis and Colitis: Not Yet Ready for the Big Leagues. ( 29620603 )
2018
7
Takayasu's arteritis associated with eosinophilic gastroenteritis, possibly via the overactivation of Th17. ( 29942355 )
2018
8
Eosinophilic gastroenteritis: An unusual presentation of a rare disease. ( 29555104 )
2018
9
Eosinophilic gastroenteritis complicating acute calculus eosinophilic cholecystitis 6 months after cholecystectomy. ( 30370999 )
2018
10
Eosinophilic gastroenteritis and other eosinophilic gut diseases distal to the oesophagus. ( 29533199 )
2018
11
Severe asthma with eosinophilic gastroenteritis effectively managed by mepolizumab and omalizumab. ( 30056148 )
2018
12
Massive hemorrhagic ascites: A rare presentation of eosinophilic gastroenteritis. ( 30079343 )
2018
13
Clinical and pathological profile of eosinophilic gastroenteritis. ( 30113369 )
2018
14
Abdominal ascites in children as the presentation of eosinophilic gastroenteritis: A surgeon's perspective. ( 30528318 )
2018
15
Eosinophilic gastroenteritis caused by eating hens' eggs: A case report. ( 28279648 )
2017
16
Eosinophilic gastroenteritis presenting as upper gastrointestinal hematoma and ulcers after endoscopic biopsy: A case report and literature review. ( 28906408 )
2017
17
A Prospective Study on the Prevalence, Extent of Disease and Outcome of Eosinophilic Gastroenteritis in Patients Presenting with Lower Abdominal Symptoms. ( 29212311 )
2017
18
CCR3 Monoclonal Antibody Inhibits Eosinophilic Inflammation and Mucosal Injury in a Mouse Model of Eosinophilic Gastroenteritis. ( 28497923 )
2017
19
Diagnosis of eosinophilic gastroenteritis is easily missed. ( 28596692 )
2017
20
Eosinophilic Ascites-Rarest Presentation of a Rare Disease, Eosinophilic Gastroenteritis. ( 29313586 )
2017
21
Serum Biomarkers for the Diagnosis of Eosinophilic Esophagitis and Eosinophilic Gastroenteritis. ( 28943560 )
2017
22
Eosinophilic Ascites: Uncommon Presentation of Eosinophilic Gastroenteritis in a Young Adult Male. ( 29255753 )
2017
23
Eosinophilic gastroenteritis: three clinical cases with different presentations. ( 28063615 )
2017
24
Post-partum eosinophilic gastroenteritis: A case report. ( 28081983 )
2017
25
Lack of Knowledge and Low Readiness for Health Care Transition in Eosinophilic Esophagitis and Eosinophilic Gastroenteritis. ( 28644350 )
2017
26
Prevalence of Eosinophilic Gastroenteritis and Colitis in a Population-Based Study, From 2012 to 2017. ( 28603057 )
2017
27
Eosinophilic Gastroenteritis Presenting with Red Streaking. ( 28250308 )
2017
28
Hematemesis as Initial Presentation in a 10-Week-Old Infant with Eosinophilic Gastroenteritis. ( 28299223 )
2017
29
Eosinophilic gastroenteritis in a teenager: A rare diagnosis. ( 27283450 )
2017
30
Eosinophilic gastroenteritis; a report of two cases with different presentations. ( 29511487 )
2017
31
Eosinophilic gastroenteritis in a woman with multiple sclerosis on dimethyl fumarate. ( 27466473 )
2016
32
Eosinophilic Esophagitis, Eosinophilic Gastroenteritis, and Eosinophilic Colitis: Common Mechanisms and Differences between East and West. ( 29922659 )
2016
33
Eosinophilic gastroenteritis: a challenge to diagnose and treat. ( 27613263 )
2016
34
A Case of Eosinophilic Gastroenteritis Forming a Rigid Chamber Mimicking Giant Duodenal Ulcer on Computed Tomography Imaging. ( 27086704 )
2016
35
Eosinophilic gastroenteritis in an 18-year-old male with prolonged nephrotic syndrome. ( 28018451 )
2016
36
Severe Eosinophilic Gastroenteritis in a Crohn's Disease Patient Treated With Infliximab and Adalimumab. ( 27018120 )
2016
37
Eosinophilic Gastroenteritis as a Rare Cause of Recurrent Epigastric Pain. ( 27274524 )
2016
38
Eosinophilic gastroenteritis: Approach to diagnosis and management. ( 27867684 )
2016
39
Eosinophilic gastroenteritis in a patient with Bruton's tyrosine kinase deficiency. ( 26840762 )
2016
40
Lack of Knowledge and Low Readiness for Healthcare Transition in Eosinophilic Esophagitis and Eosinophilic Gastroenteritis. ( 27657884 )
2016
41
Eosinophilic Gastroenteritis: An Underdiagnosed Condition. ( 27234270 )
2016
42
Eosinophilic gastroenteritis: A state-of-the-art review. ( 27253425 )
2016
43
Severe eosinophilic gastroenteritis. ( 26802190 )
2016
44
Sera of patients with infantile eosinophilic gastroenteritis showed a specific increase in both thymic stromal lymphopoietin and IL-33 levels. ( 26948075 )
2016
45
Eosinophilic Gastroenteritis: Case Report and Review in Search for Diagnostic Key Points. ( 26075112 )
2015
46
Clinical characteristics, treatment outcomes, and resource utilization in children and adults with eosinophilic gastroenteritis. ( 25547198 )
2015
47
A Case of Eosinophilic Gastroenteritis with Ascites. ( 26819619 )
2015
48
Eosinophilic gastroenteritis due to rhus ingestion presenting with gastrointestinal hemorrhage. ( 25844348 )
2015
49
Perforated duodenal ulcer: An unusual manifestation of allergic eosinophilic gastroenteritis. ( 26640348 )
2015
50
Eosinophilic Gastroenteritis with Ascites in a Child. ( 26388635 )
2015

Variations for Eosinophilic Gastroenteritis

Expression for Eosinophilic Gastroenteritis

Search GEO for disease gene expression data for Eosinophilic Gastroenteritis.

Pathways for Eosinophilic Gastroenteritis

GO Terms for Eosinophilic Gastroenteritis

Cellular components related to Eosinophilic Gastroenteritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.5 ALB CCL11 EPX IL3 IL5 RNASE3
2 extracellular space GO:0005615 9.17 ALB CCL11 EPX IL3 IL5 RNASE3

Biological processes related to Eosinophilic Gastroenteritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.54 CCL11 IL3 IL5
2 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.32 IL3 IL5
3 cellular oxidant detoxification GO:0098869 9.26 ALB EPX
4 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.16 IL3 TSLP
5 cytokine-mediated signaling pathway GO:0019221 9.13 CCL11 IL3 IL5
6 regulation of signaling receptor activity GO:0010469 8.92 CCL11 IL3 IL5 TSLP

Molecular functions related to Eosinophilic Gastroenteritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 8.92 CCL11 IL3 IL5 TSLP

Sources for Eosinophilic Gastroenteritis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....